| Title: |
Mutations on OAS1 Genes |
| Document Number: |
20120070424 |
| Publication Date: |
March 22, 2012 |
| Appl. No: |
13/180132 |
| Application Filed: |
July 11, 2011 |
| Abstract: |
Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided. |
| Inventors: |
Iadonato, Shawn P. (Seattle, WA, US); Magness, Charles L. (Seattle, WA, US); Fellin, P. Campion (Seattle, WA, US); Scherer, Christina A. (Seattle, WA, US); Hagen, Tory (Tacoma, WA, US); Olson, Amy (Seattle, WA, US) |
| Claim: |
1-28. (canceled) |
| Claim: |
29. An oligoadenylate synthetase 1 protein consisting of the amino acid sequence of SEQ ID NO:1 having at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, and/or 335, and wherein the amino acid at position 162 is Gly. |
| Claim: |
30. The protein of claim 29 having at least one amino acid modification at position 1, 31, 115, 127, 295 and/or 315. |
| Claim: |
31. The protein of claim 30 wherein the amino acid at position 1 is deleted. |
| Claim: |
32. The protein of claim 30 wherein the amino acid at position 31 is Asp or Asn, the amino acid at position 115 is Leu or Phe, the amino acid at position 127 is Gly or Arg, the amino acid at position 295 is Arg or Thr, and the amino acid at position 315 is Gly or Arg. |
| Claim: |
33. The protein of claim 29 wherein the amino acid at position 24 is Lys or Thr, the amino acid at position 25 is His or Cys, the amino acid at position 28 is Thr, Lys, or Met, the amino acid at position 36 is Thr or Ile, the amino acid at position 47 is Gln or Arg, the amino acid at position 53 is Ala or Val, the amino acid at position 54 is Arg, His or Cys, the amino acid at position 64 is Phe or Ser, the amino acid at position 69 is Ala, Ser or Thr, the amino acid at position 74 is Ile or Ser, the amino acid at position 104 is Lys or Arg, the amino acid at position 108 is Val or Ala, the amino acid at position 113 is Ser or Arg, the amino acid at position 114 is Ile or Ala, the amino acid at position 116 is Arg, Ser or Ala, the amino acid at position 117 is Glu or Val, the amino acid at position 118 is Val or Lys, the amino acid at position 119 is Phe, the amino acid at position 127 is Asp or Gly, the amino acid at position 130 is Cys or Arg, the amino acid at position 139 is Phe or Leu, the amino acid at position 142 is Arg or Gly, the amino acid at position 160 is Ile or Thr, the amino acid at position 161 is Asp or Gly, the amino acid at position 166 is Asp or Asn, the amino acid at position 175 is Lys or Glu, the amino acid at position 179 is Tyr or Asp, the amino acid at position 200 is Glu or Gln, the amino acid at position 242 is Gln or Arg, the amino acid at position 246 is Glu or Lys, the amino acid at position 248 is Asp or His, the amino acid at position 250 is Ile or Asn, the amino acid at position 254 is Glu or Gly, the amino acid at position 274 is Val or Lys, the amino acid at position 279 is Glu or Lys, the amino acid at position 282 is Ser or Ile, the amino acid at position 284 is Lys or Glu, the amino acid at position 288 is Ser or Arg, the amino acid at position 292 is Glu, Thr, Arg, or Ser, and the amino acid at position 314 is Ile or Lys, and the amino acid at position 335 is Trp or terminated. |
| Claim: |
34. The protein of claim 33 wherein the amino acid at position 1 is deleted. |
| Claim: |
35. The oligoadenylate synthetase 1 protein of claim 29 consisting of amino acids 1-334 of the amino acid sequence of SEQ ID NO:1. |
| Claim: |
36. A therapeutic composition for treating or preventing infection by a virus in a mammal or for treating cancer in a mammal wherein the composition comprises a pharmaceutically acceptable carrier and an oligoadenylate synthetase 1 protein consisting of the amino acid sequence of SEQ ID NO:1 having at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, and/or 335, and wherein the amino acid at position 162 is Gly. |
| Claim: |
37. The composition of claim 36 wherein the protein has at least one amino acid modification at position 1, 31, 115, 127, 295 and/or 315. |
| Claim: |
38. The composition of claim 36 wherein in the protein the amino acid at position 1 is deleted. |
| Claim: |
39. The composition of claim 36 wherein in the protein the amino acid at position 31 is Asp or Asn, the amino acid at position 115 is Leu or Phe, the amino acid at position 127 is Gly or Arg, the amino acid at position 295 is Arg or Thr, and the amino acid at position 315 is Gly or Arg. |
| Claim: |
40. The composition of claim 36 wherein in the protein the amino acid at position 24 is Lys or Thr, the amino acid at position 25 is His or Cys, the amino acid at position 28 is Thr, Lys, or Met, the amino acid at position 36 is Thr or Ile, the amino acid at position 47 is Gln or Arg, the amino acid at position 53 is Ala or Val, the amino acid at position 54 is Arg, His or Cys, the amino acid at position 64 is Phe or Ser, the amino acid at position 69 is Ala, Ser or Thr, the amino acid at position 74 is Ile or Ser, the amino acid at position 104 is Lys or Arg, the amino acid at position 108 is Val or Ala, the amino acid at position 113 is Ser or Arg, the amino acid at position 114 is Ile or Ala, the amino acid at position 116 is Arg, Ser or Ala, the amino acid at position 117 is Glu or Val, the amino acid at position 118 is Val or Lys, the amino acid at position 119 is Phe, the amino acid at position 127 is Asp or Gly, the amino acid at position 130 is Cys or Arg, the amino acid at position 139 is Phe or Leu, the amino acid at position 142 is Arg or Gly, the amino acid at position 160 is Ile or Thr, the amino acid at position 161 is Asp or Gly, the amino acid at position 166 is Asp or Asn, the amino acid at position 175 is Lys or Glu, the amino acid at position 179 is Tyr or Asp, the amino acid at position 200 is Glu or Gln, the amino acid at position 242 is Gln or Arg, the amino acid at position 246 is Glu or Lys, the amino acid at position 248 is Asp or His, the amino acid at position 250 is Ile or Asn, the amino acid at position 254 is Glu or Gly, the amino acid at position 274 is Val or Lys, the amino acid at position 279 is Glu or Lys, the amino acid at position 282 is Ser or Ile, the amino acid at position 284 is Lys or Glu, the amino acid at position 288 is Ser or Arg, the amino acid at position 292 is Glu, Thr, Arg, or Ser, and the amino acid at position 314 is Ile or Lys. |
| Claim: |
41. The composition of claim 36 wherein in the protein the amino acid at position 1 is deleted. |
| Claim: |
42. The composition of claim 36 wherein the virus is a flavivirus. |
| Claim: |
43. The composition of claim 36 wherein the virus is hepatitis C virus. |
| Claim: |
44. The composition of claim 36 wherein the virus is selected from the group consisting of respiratory syncytial virus and Dengue virus. |
| Claim: |
45. The composition of claim 36 wherein the composition is provided as part of a kit. |
| Claim: |
46. A kit comprising the composition of claim 45, wherein the kit comprises instructions prescribed by a governmental agency. |
| Claim: |
47. An oligoadenylate synthetase 1 protein consisting of amino acids 1-353 of SEQ ID NO:2 ID NO:2, wherein the protein has at least one amino acid modification at position 1, 24, 25, 28, 31, 36, 47, 53, 54, 64, 69, 74, 104, 108, 112, 113, 114, 115, 116, 117, 118, 119, 127, 130, 139, 142, 160, 161, 166, 175, 179, 226, 242, 246, 248, 250, 254, 274, 279, 282, 284, 288, 289, 292, 295, 314, 315, 335, 347, 350, 352, and/or 353, and wherein the amino acid at position 162 is Gly. |
| Claim: |
48. A therapeutic composition for treating or preventing infection by a virus in a mammal or for treating cancer in a mammal wherein the composition comprises a pharmaceutically acceptable carrier and the oligoadenylate synthetase 1 protein of claim 47. |
| Current U.S. Class: |
424/945 |
| Current International Class: |
61; 61; 61; 12; 61 |
| Accession Number: |
edspap.20120070424 |
| Database: |
USPTO Patent Applications |
